blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3039020

EP3039020 - IDO INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.05.2018
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  16.06.2017
FormerGrant of patent is intended
Status updated on  23.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2016/27]
Inventor(s)01 / MARKWALDER, Jay A.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
02 / SEITZ, Steven P.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
03 / BALOG, James Aaron
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
04 / HUANG, Audris
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
05 / WILLIAMS, David K.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
06 / CHEN, Libing
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
07 / MANDAL, Sunil Kumar
c/o SYNGENE INTERNATIONAL LIMITED
Biocon Park Plot Nos. 2&3
Bommasandra IV Phase
Jigani Line Road
Bangalore Karnataka 560 099 / IN
08 / SRIVASTAVA, Shefali
K 604, City OF Golden Dome
Rov. Jagatpura
Jaipur 302017 / IN
 [2016/27]
Representative(s)Reitstötter Kinzebach
Patentanwälte
Sternwartstraße 4
81679 München / DE
[N/P]
Former [2016/27]Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
Application number, filing date14766038.526.08.2014
[2016/27]
WO2014US52600
Priority number, dateUS201361870371P27.08.2013         Original published format: US 201361870371 P
[2016/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015031295
Date:05.03.2015
Language:EN
[2015/09]
Type: A1 Application with search report 
No.:EP3039020
Date:06.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application.
[2016/27]
Type: B1 Patent specification 
No.:EP3039020
Date:19.07.2017
Language:EN
[2017/29]
Search report(s)International search report - published on:EP05.03.2015
ClassificationIPC:C07D403/12, C07D309/14, C07D215/06, C07D231/12, C07D333/10, C07D401/12, C07D409/12, C07D411/12, C07D413/12, C07D257/04, C07D277/22, C07C13/00, A61K31/416, A61P37/02
[2016/27]
CPC:
C07D257/04 (EP,US); A61K31/17 (EP,US); A61K31/18 (EP,US);
A61K31/381 (EP,US); A61K31/41 (EP,US); A61K31/422 (EP,US);
A61K31/427 (EP,US); A61K31/4439 (EP,US); A61K31/451 (EP,US);
A61K31/4709 (EP,US); A61K31/497 (EP,US); A61K31/50 (EP,US);
A61K31/506 (EP,US); A61K31/5375 (EP,US); A61K45/06 (US);
A61P25/24 (EP); A61P31/12 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P43/00 (EP); C07B59/002 (EP,US); C07C275/42 (EP,US);
C07C311/05 (EP,US); C07C311/09 (EP,US); C07C317/44 (EP,US);
C07D211/14 (EP,US); C07D215/06 (EP,US); C07D231/12 (EP,US);
C07D237/20 (EP,US); C07D277/22 (EP,US); C07D309/14 (EP,US);
C07D333/10 (EP,US); C07D333/38 (EP,US); C07D401/10 (EP,US);
C07D401/12 (EP,US); C07D403/12 (EP,US); C07D407/12 (EP,US);
C07D409/12 (EP,US); C07D411/12 (EP,US); C07D413/12 (EP,US);
C07D417/12 (EP,US); C07C2601/02 (EP,US); C07C2601/04 (EP,US);
C07C2601/08 (EP,US); C07C2601/14 (EP,US); C07C2601/16 (EP,US);
C07C2601/18 (EP,US); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:IDO-HEMMER[2016/27]
English:IDO INHIBITORS[2016/27]
French:INHIBITEURS D'IDO[2016/27]
Entry into regional phase24.03.2016National basic fee paid 
24.03.2016Designation fee(s) paid 
24.03.2016Examination fee paid 
Examination procedure24.03.2016Examination requested  [2016/27]
27.10.2016Amendment by applicant (claims and/or description)
24.02.2017Communication of intention to grant the patent
06.06.2017Fee for grant paid
06.06.2017Fee for publishing/printing paid
06.06.2017Receipt of the translation of the claim(s)
Opposition(s)20.04.2018No opposition filed within time limit [2018/26]
Fees paidRenewal fee
11.08.2016Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.08.2014
AL19.07.2017
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
PT19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
[2020/34]
Former [2020/28]HU26.08.2014
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
PT19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2020/15]HU26.08.2014
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2019/52]HU26.08.2014
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2019/47]HU26.08.2014
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2019/31]HU26.08.2014
AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/43]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
MT26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/39]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/34]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SK19.07.2017
SM19.07.2017
IE26.08.2017
LU26.08.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/24]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SK19.07.2017
SM19.07.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/21]AT19.07.2017
CZ19.07.2017
DK19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
CH31.08.2017
LI31.08.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/12]AT19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/11]AT19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/10]AT19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
NL19.07.2017
RS19.07.2017
SE19.07.2017
NO19.10.2017
Former [2018/09]FI19.07.2017
LT19.07.2017
NL19.07.2017
SE19.07.2017
NO19.10.2017
Former [2018/08]FI19.07.2017
LT19.07.2017
NL19.07.2017
NO19.10.2017
Former [2018/07]LT19.07.2017
NO19.10.2017
Cited inInternational search[A]WO2007075598  (INCYTE CORP [US], et al) [A] 1-15 * claim 1 *;
 [A]WO2008058178  (INCYTE CORP [US], et al) [A] 1-15 * claim 1 *;
 [AP]  - EDUARD DOLUSIC ET AL, "Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012)", EXPERT OPINION ON THERAPEUTIC PATENTS, (20131001), vol. 23, no. 10, doi:10.1517/13543776.2013.827662, ISSN 1354-3776, pages 1367 - 1381, XP055118624 [AP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1517/13543776.2013.827662
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.